Ondine Biomedical Inc. Issue of Equity (2537Y)
03 May 2023 - 4:56PM
UK Regulatory
TIDMOBI
RNS Number : 2537Y
Ondine Biomedical Inc.
03 May 2023
3 May 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Issue of Equity
Total Voting Rights
Ondine Biomedical Inc. (AIM: OBI) announces the issue of 390,550
common shares in the Company (the "Consideration Shares") to Hylife
pursuant to the services agreement entered into on 15 December 2020
("Hylife Service Agreement"). Further details of the services
provided under the Hylife Service Agreement are included in the
Company's Admission Document dated 1 December 2021.
In accordance with the Hylife Service Agreement, the
Consideration Shares are being issued at a price of $1.53421 USD
per Consideration Share.
Admission and Total Voting Rights
Application is being made for the admission to trading on AIM
("Admission") of the 390,550 Consideration Shares, which will rank
pari passu in all respects with the Company's existing common
shares. Admission of the Consideration Shares is expected to become
effective on 5 May 2023.
Following Admission, the total number of common shares in the
Company with voting rights will be 194,983,407 . The Company does
not hold any shares in Treasury. The above figure of 194,983,407
common shares may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company.
Ondine Biomedical Inc.
+001 (1) 604 838
Angelika Vance, Corporate Communications 2702
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0) 20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0) 77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Ondine's nasal photodisinfection technology is approved in several
jurisdictions under the brand name Steriwave(TM). It has been
awarded the CE mark and, in the US, has been granted Qualified
Infectious Disease Product designation and Fast Track status by the
FDA. Products beyond nasal photodisinfection include therapies for
a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOENKNBPABKKPPK
(END) Dow Jones Newswires
May 03, 2023 02:56 ET (06:56 GMT)
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From Apr 2024 to May 2024
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From May 2023 to May 2024